AstraZeneca CEO Pascal Soriot highlighted that artificial intelligence (AI) is significantly enhancing the company's ability to develop medicines faster and make smarter research decisions. AI tools help identify promising drug targets, optimize molecules to reduce side effects, and improve the chances of success in costly clinical trials. Through partnerships with Tempus AI and Pathos, AstraZeneca uses AI models to analyze clinical and laboratory data, increasing the probability of success in late-stage trials and improving productivity. This advancement could save hundreds of millions of dollars per trial and accelerate innovation across AstraZeneca's drug pipeline.
AstraZeneca PLC shares fell over 6% following the failure of Wainua (eplontersen) in its Phase 3 ATTR-CM trial, which represents a significant lost revenue opportunity. Ionis Pharmaceuticals, which developed eplontersen and stands to earn royalties, ...
The FTSE 100 fell due to AstraZeneca's 8% drop after a failed clinical trial for a heart disease drug, impacting its market value by £20 billion. Meanwhile, Computacenter surged over 13% following a strong trading update, and US semiconductor stocks ...
AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present v...
AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit...
AstraZeneca's shares fell 9.55%, wiping £19 billion off its value, after its Wainua drug failed a major Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial did not meet its primary goal of reducing cardiovascular de...
